Jonathan Douxfils

2026

A detailed review of pharmacokinetics/pharmacodynamics of progestogens in oral contraception.

Frontiers in endocrinology ·doi:10.3389/fendo.2026.1730768

Many different progestogens are used by millions of women worldwide for oral contraception, either alone (Progestogen-only Pills [POPs]) or as combined oral contraceptives (COCs) comprising a synthetic estrogen (ethinyl estradiol [EE]), or …

review 2026

Venous Thromboembolism Risk Associated With Relugolix-estradiol-norethisterone Acetate Combination Therapy

Journal of the Endocrine Society ·doi:10.1210/jendso/bvaf190

BACKGROUND: Relugolix, an oral GnRH receptor antagonist, is effective in treating uterine myomas and endometriosis. However, concerns persist regarding the venous thromboembolism (VTE) risk associated with its combination with oral estradio…

rct 2024

Impact of Estetrol Combined with Drospirenone on Blood Coagulation and Fibrinolysis in Patients with Endometriosis: A Multicenter, Randomized, Open-Label, Active-Controlled, Parallel-Group Study

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis ·doi:10.1177/10760296241286514

Venous thromboembolism is a serious safety concern in women using combined oral contraceptives; ethinyl estradiol (EE) is widely used as an estrogen. Estetrol (E4) is a native estrogen with selective tissue activity and exclusively produced…

2021

Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk.

Frontiers in endocrinology ·doi:10.3389/fendo.2021.769187

Many factors must be considered and discussed with women when initiating a contraceptive method and the risk of venous thromboembolism (VTE) is one of them. In this review, we discuss the numerous strategies that have been implemented to re…